NCCN Guidelines Insights: T-Cell Lymphomas, Version 1.2021-Reference-Cited by-同舟云学术

NCCN Guidelines Insights: T-Cell Lymphomas, Version 1.2021

Published:2020-11 Issue:11 Volume:18 Page:1460-1467
ISSN:1540-1405
Container-title:Journal of the National Comprehensive Cancer Network
language:
Short-container-title:

Author:

Horwitz Steven M.¹,Ansell Stephen²,Ai Weiyun Z.³,Barnes Jeffrey⁴,Barta Stefan K.⁵,Clemens Mark W.⁶,Dogan Ahmet¹,Goodman Aaron M.⁷,Goyal Gaurav⁸,Guitart Joan⁹,Halwani Ahmad¹⁰,Haverkos Bradley M.¹¹,Hoppe Richard T.¹²,Jacobsen Eric¹³,Jagadeesh Deepa¹⁴,Jones Allison¹⁵,Kim Youn H.¹²,Mehta-Shah Neha¹⁶,Olsen Elise A.¹⁷,Pro Barbara⁹,Rajguru Saurabh A.¹⁸,Rozati Sima¹⁹,Said Jonathan²⁰,Shaver Aaron²¹,Shustov Andrei²²,Sokol Lubomir²³,Torka Pallawi²⁴,Torres-Cabala Carlos⁶,Wilcox Ryan²⁵,William Basem M.²⁶,Zain Jasmine²⁷,Dwyer Mary A.²⁸,Sundar Hema²⁸

Affiliation:

1. 1Memorial Sloan Kettering Cancer Center;

2. 2Mayo Clinic Cancer Center;

3. 3UCSF Helen Diller Family Comprehensive Cancer Center;

4. 4Massachusetts General Hospital Cancer Center;

5. 5Abramson Cancer Center at the University of Pennsylvania;

6. 6The University of Texas MD Anderson Cancer Center;

7. 7UC San Diego Moores Cancer Center;

8. 8O'Neal Comprehensive Cancer Center at UAB;

9. 9Robert H. Lurie Comprehensive Cancer Center of Northwestern University;

10. 10Huntsman Cancer Institute at the University of Utah;

11. 11University of Colorado Cancer Center;

12. 12Stanford Cancer Institute;

13. 13Dana-Farber/Brigham and Women's Cancer Center;

14. 14Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute;

15. 15St. Jude Children's Research Hospital/The University of Tennessee Health Science Center;

16. 16Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine;

17. 17Duke Cancer Institute;

18. 18University of Wisconsin Carbone Cancer Center;

19. 19The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;

20. 20UCLA Jonsson Comprehensive Cancer Center;

21. 21Vanderbilt-Ingram Cancer Center;

22. 22Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance;

23. 23Moffitt Cancer Center;

24. 24Roswell Park Comprehensive Cancer Center;

25. 25University of Michigan Rogel Cancer Center;

26. 26The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute;

27. 27City of Hope National Medical Center; and

28. 28National Comprehensive Cancer Network.

Abstract

Hepatosplenic T-cell lymphoma (HSTCL) is a rare subtype of T-cell lymphoma associated with an aggressive clinical course and a worse prognosis. HSTCL develops in the setting of chronic immune suppression or immune dysregulation in up to 20% of cases and is most often characterized by spleen, liver, and bone marrow involvement. Diagnosis and management of HSTCL pose significant challenges given the rarity of the disease along with the absence of lymphadenopathy and poor outcome with conventional chemotherapy regimens. These Guidelines Insights focus on the diagnosis and treatment of HSTCL as outlined in the NCCN Guidelines for T-Cell Lymphomas.

Publisher

Harborside Press, LLC

Subject

Oncology

Link

https://jnccn.org/downloadpdf/journals/jnccn/18/11/article-p1460.xml

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Monomorphic epitropic intestinal T-cell lymphoma presenting with intestinal perforation;Asian Journal of Surgery;2024-01

2. Long-term Outcomes After Hematopoietic Cell Transplant in Peripheral T-Cell Lymphoma – The Oregon Health and Science University Experience;Clinical Lymphoma Myeloma and Leukemia;2023-12

3. Development of a radiomic-clinical nomogram for prediction of survival in patients with nasal extranodal natural killer T-cell lymphoma;2023-11-14

4. Itchy Skin: A Challenging Differential Diagnosis Between Mycosis Fungoides and Sézary Syndrome;Cureus;2023-10-03

5. Comparison of first-line treatment with CHOP versus ICED in patients with peripheral T-cell lymphoma eligible for upfront autologous stem cell transplantation;Frontiers in Oncology;2023-08-22